pdf   xlsx method abbreviations

mBC - TNBC - L1 - PDL1 positive, pembrolizumab plus SoC , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.82 [0.70, 0.95]< 10%2 studies (2/-)99.5 %lownot evaluable highcrucial-
progression or deaths (PFS) 0.72 [0.61, 0.84]< 10%2 studies (2/-)100.0 %lownot evaluable highimportant-
objective responses (ORR) 1.39 [1.06, 1.83]> 10%2 studies (2/-)99.0 %lownot evaluable highnon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.